Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...

With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 ...

The global rheumatoid arthritis drugs market was valued at US$31.27 billion in 2024 and is projected to reach US$56.62 billion by 2033, ...

This lens points to three standouts in retail, healthcare, and consumer goods. One pairs a modest yield with rapid hikes ...

ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...

Clinique La Prairie, the world-renowned Swiss pioneer in longevity, health, and wellness, proudly announces the U.S. retail debut of its core line of longevity supplements, branded CLP HOLISTIC HEALTH ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

Shattuck Labs, Inc. ( NASDAQ: STTK) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT ...

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...